A mathematical model of the kinetics of β-amyloid fibril growth from the denatured state

Biophysical Journal

Volumn 81, Issue 3, 2001, Pages 1805-1822

  Pallitto, Monica M ^a   Murphy, Regina M ^a  

^a University of Wisconsin Madison   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; DIMER; MONOMER; PHOSPHATE; UREA;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CELL STRAIN; GEL PERMEATION CHROMATOGRAPHY; KINETICS; LIGHT SCATTERING; MATHEMATICAL MODEL; NONHUMAN; PROTEIN AGGREGATION; PROTEIN DENATURATION; PROTEIN FOLDING; RAT;

EID: 0034875603     PISSN: 00063495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3495(01)75831-6     Document Type: Article

References (75)

1. Solution conformations and aggregational properties of synthetic amyloid β peptides of AD
2. ApoE associated with lipid has a reduced capacity to inhibit β-amyloid fibril formation
3. Static and dynamic light scattering from branched polymers and biopolymers
4. Assembly and aggregation properties of synthetic Alzheimer's A4/β amyloid peptide analogs
5. Rapid induction of Alzheimer A beta amyloid formation by zinc
6. Sensitivity analysis of initial value problems with mixed ODEs and algebraic equations
7. Mutational analysis of the propensity for amyloid formation by a globular protein
8. The interaction between Alzheimer amyloid β(1-40) peptide and ganglioside GM1-containing membranes
9. The protein folding problem
10. Alzheimer's disease amyloid propagation by a template-dependent dock-lock mechanism
11. Modified-peptide inhibitors of amyloid β-peptide polymerization
12. Protein aggregation: Folding aggregates, inclusion bodies, and amyloid
13. Morphology and antibody recognition of synthetic beta-amyloid peptides
14. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
15. A strategy for designing inhibitors of β-amyloid toxicity
16. Exposure of hydrophobic surfaces on the chaperonin GroEL oligomer by protonation or modification of His-401
17. Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein
18. A kinetic study of the competition between renaturation and aggregation during refolding of denatured-reduced egg white lysozyme
19. Observation of metastable Aβ amyloid protofibrils by atomic force microscopy
20. Assembly of Aβ amyloid protofibrils: An in vitro model for a possible early event in Alzheimer's disease
21. Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons
22. Length dependence of rate constants for end-to-end association and dissociation of equilibrium linear aggregates
23. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes
24. Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer β-amyloid fibril formation
25. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice
26. Structural studies of soluble oligomers of the Alzheimer β-amyloid peptide
27. 2-Macroglobulin associates with β-amyloid peptide and prevents fibril formation
28. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease
29. The seminal role of β-amyloid in the pathogenesis of Alzheimer disease
30. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
31. Amyloid diseases: Abnormal protein aggregation in neurodegeneration
32. In situ atomic force microscopy study of Alzheimer's beta-amyloid peptide on different substrates: New insights into mechanism of beta-sheet formation
33. Light scattering of stiff chain polymers
34. Correlation of β-amyloid aggregate size and hydrophobicity with decreased bilayer fluidity of model membranes
35. Controlling polymerization of β-amyloid and prion-derived peptides with synthetic small molecule ligands
36. Diffusible, nonfibrillar ligands derived from Abeta (1-42) are potent central nervous system neurotoxins
37. Evolution of amyloid: What normal protein folding may tell us about fibrillogenesis and disease
38. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions
39. On the nucleation and growth of amyloid β-protein fibrils: Detection of nuclei and quantitation of rate constants
40. Kinetic theory of fibrillogenesis of amyloid β-protein
41. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red
42. Structure-function relationships for inhibitors of β-amyloid toxicity containing the recognition sequence KLVFF
43. 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments
44. Structural analysis of Alzheimer's β(1-40) amyloid: Protofilament assembly of tubular fibrils
45. Amyloid plaque core proteins in Alzheimer disease and Down syndrome
46. β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity
47. Interactions of Alzheimer amyloid-β peptides with glycosaminoglycans
48. Probing the kinetics of beta-amyloid self-association
49. First-order kinetic model of Alzheimer's β-amyloid fibril extension in vitro
50. High density lipoprotein inhibits assembly of amyloid β-peptides into fibrils
51. Recognition sequence design for peptidyl modulators of β-amyloid aggregation and toxicity
52. Neurodegeneration induced by β-amyloid peptides in vitro: The role of peptide assembly state
53. Morphology and toxicity of Aβ-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease
54. The toxicity of the Alzheimer's β-amyloid peptide correlates with a distinct fiber morphology
55. Effect of acid predissolution on fibril size and fibril flexibility of synthetic β-amyloid peptide
56. Solvent effects on self-assembly of β-amyloid peptide
57. Secondary structure of amyloid β peptide correlates with neurotoxic activity in vitro
58. Suffactant properties of Alzheimer's Aβ peptides and the mechanism of amyloid aggregation
59. The conformation of Alzheimer's β-peptide determines the rate of amyloid formation and its resistance to proteolysis
60. Inhibition of Alzheimer's amyloidosis by peptides that prevent β-sheet conformation
61. Multiresponse parameter estimation with a new and noninformative prior
62. The nanometer-scale structure of amyloid-β visualized by atomic force microscopy
63. Aggregation of Aβ Alzheimer's disease-related peptide studied by dynamic light scattering
64. Controlling amyloid β-peptide fibril formation with protease-stable ligands
65. Kinetics of aggregation of synthetic β-amyloid peptide
66. Deposition of monomeric, not oligomeric, Aβ mediates growth of Alzheimer's disease amyloid plaques in human brain preparations
67. Fractionation and characterization of oligomeric, protofibrillar and fibrillar forms of β-amyloid peptide
68. De novo amyloid proteins from designed combinatorial libraries
69. Selective inhibition of Abeta fibril formation
70. Deposits of Aβ fibrils are not toxic to cortical and hippocampal neurons in vitro
71. Translational friction coefficient of wormlike chains
72. Neurotrophic and neurotoxic effects of amyloid β-protein: Reversal by tachykinin neuropeptides